secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001193125-25-043544
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics raises ~$7.1M via ADS/warrant offering with board participation
--------------------------------------------------------------------------------

- Gross proceeds ~$7.1M from sale of 6,637,626 ADS units (or prefunded warrants) plus Series A/B warrants; includes $1M note termination by Chairman.
- ADS unit purchase price: $0.87 plus $0.25–$0.3125 premium per tier; warrants exercisable at $0.87.
- Series A warrants expire 1 year, Series B warrants expire 5 years from closing.
- Chairman Dr. Hoyoung Huh, CEO Dr. Samir Patel, and all board members participating; $1M note terminated.
- Proceeds for working capital; resale registration statement to be filed within 60 days of closing (expected March 5).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000119312525043544/0001193125-25-043544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000119312525043544/d803084d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-043544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer